Application of polymeric nanoparticles in oral delivery of recombinant human erythropoietin: A review
Recombinant Human Erythropoietin drugs are known as erythropoietin stimulating agents which stimulate the bone marrow to produce more red blood cells in the body. It is used an antianemic in the treatment of renal anemia and chemotherapy induced anemia. It also use in treatment of HIV, cerebral malaria and neurological disease like schizophrenia. The recombinant human erythropoietin dosage form currently available in the market is parenteral dosage form that is ready for injection liquid vial (syringe), which is usually administered 2-3 times weekly. To achieve a therapeutic effect of parenterally administered EPO, cumulative doses are required that significantly exceed levels of endogenous EPO. These high serum levels result in prolonged circulation times of EPO and unspecific binding to non-targeted tissue, which may lead to severe undesired side effects i.e. growth of tumor and also increased risk of death. By using the nanotechnology, side effects and toxicity related to high dose of erythropoietin should be reduces and prolong drug release. this will achieve by reducing administration frequency and lowering dosage of erythropoietin.
Keywords: Recombinant Human Erythropoietin, Nanoparticle, Prolong drug release, Anemia
2. Tatkare D , Global Opportunity Analysis and Industry Forecast, 2015; 115:2013-2020
3. Mateja C, Barbara P, Porekar V, Gaberc S, Mateja N, Spela J, Radovan K, Simon C, Erythropoietin conjugates having oral bioavailability. https//www.google.com/patent/ 2015; 032981? cl= en & utm_source=gb-gplus-sharePatent WO2015032981A1
4. Woitiski CB, Carvalho RA, Ribeiro AJ, Neufeld RJ, Veiga F. Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation. BioDrugs 2008; 22:223e37.
5. Herrero EP, Alonso MJ, Saba N. Polymer-based oral peptide nanomedicines. Ther Deliv 2012; 3:657e68.
6. Damge C, Maincent P, Ubrich N. Oral delivery of insulin associated to polymeric nanoparticles in diabetic rats. J Control Release 2007; 117:163e70.
7. Li CL, Deng YJ. Oil-based formulations for oral delivery of insulin. J Pharm Pharmacol 2004; 56:1101e7.
8. Eaimtrakarn S, Rama Prasad YV, Ohno T, Konishi T, Yoshikawa Y, Shibata N, Takada K. Absorption enhancing effect of Labrasol on the intestinal absorption of insulin in rats. J Drug Target 2002; 10:255e60.
9. Damge C, Reis CP, Maincent P. Nanoparticle strategies for the oral delivery of insulin. Expert Opin Drug Deliv 2008; 5:45e68.
10. Kinesh VP, Neelam DP, Punit BP, Bhavesh SB, Pragna KS. Novel approaches for oral delivery of insulin and current status of oral insulin products. Int J Pharm Sci Nanotech 2010; 3:1058e64.
11. Patel J, Chauhan S, Seth A, Formulation & Evaluation of Methotrexate Loaded Nanoparticle. International Journal of Drug Discovery and Medical Research, 2012; 2:1:56-60.
12. Sharma G, Sharma A, Nam J, George P, Doss C, Lee S, Nanoparticle based insulin delivery system. Next generation efficient therapy for Type 1 diabetes. Journal of Nanobiotechnology 2015; 13:74.
13. Manthena V, Varma S, Ashokraj Y, Dey C, Panchagnula R, P-glycoprotein inhibitors and their screening: a perspective from bioavailability enhancement. Pharmacological Research, 2003, 48:4:347-359.
14. Singhal G, Bhavesh R., Kasariya K, et al., Biosynthesis of silver nanoparticles using Ocimum sanctum (Tulsi) leaf extract and screening its antimicrobial activity. Journal of Nanoparticle Research, 2011; 13:7:2981–2988.
15. Singhal G, Bhavesh R, Sharma A, Singh R, Ecofriendly Biosynthesis of Gold Nanoparticles Using Medicianally Important Ocimum basilicum Leaf Extract. Adv. Sci. Eng. Med, 2012; 4:62-66.
16. Kumari A, Yadav S, Yadav S, Biodegradable polymeric nanoparticles based drug delivery systems. Colloids and Surfaces B: Biointerfaces, 2010; 75:1–18.
17. Chakraborty C, Pal S, Doss GP, Wen ZH, Lin CS. Nanoparticles as smart pharmaceutical delivery. Front Biosci (Landmark Ed), 2013; 1:18:1030–1050.
18. Rieux A, Fievez V, Garinot M, Schneider YJ, Preat V. Nanoparticles as potential oral delivery systems of proteins and vaccines: a mechanistic approach. J Control Release, 2006; 116:1:1–27.
19. Singh R, Lillard JW, Nanoparticle based targeted drug delivery. Exp Mol Pathol, 2009; 86:3:215–223.
20. Woitiski CB, Carvalho RA, Ribeiro AJ, Neufeld RJ, Veiga F. Strategies toward the improved oral delivery of insulin nanoparticles via gastrointestinal uptake and translocation. BioDrugs 2008; 22:223e37.
21. Chen MC, Mi FL, Liao ZX, Hsiao CW, Sonaje K, Chung MF, Hsu LW, Sung HW. Recent advances in chitosan-based nanoparticles for oral delivery of macromolecules. Adv Drug Deliver Rev 2013; 6:865e79.
22. Sonaje K, Chen YJ, Chen HL,Wey SP, Juang JH, Nguyen HN, Hsu CW, Lin KJ, SungHW. Enteric-coated capsules filled with freeze-dried chitosan/poly(gamma-glutamic acid) nanoparticles for oral insulin delivery. Biomaterials 2010; 31:3384e94.
23. Radwan MA, Aboul-Enein HY. The effect of absorption enhancers on the initial degradation kinetics of insulin by alpha-chymotrypsin. Int J Pharm 2001; 217:111e20.
24. Su FY, Lin KJ, Sonaje K, Wey SP, Yen TC, Ho YC, Panda N, Chuang EY, Maiti B, Sung HW. Protease inhibition and absorption enhancement by functional nanoparticles for effective oral insulin delivery. Biomaterials 2012; 33:2801e11.
25. Park K, Kwon IC, Park K. Oral protein delivery: current status and future prospect. React Funct Polym 2011; 71:280e7.
26. Jain, A., & Jain, S. K. l-Valine appended PLGA nanoparticles for oral insulin delivery. Acta Diabetologica, 2015; 52(4):663–676
27. Fayed B, Tawfik AK, Yassin AE, Novel erythropoietin-loaded nanoparticles with prolonged in vivo response, Journal of Microencapsulation, 2012, 1–7.
28. Ehrenreich H, Degner D, Meller J, et al. Erythropoietin: a candidate compound for neuroprotection in schizophrenia. Molecular psychiatry, 2004; 9(1):42–54.
29. Florence AT. Issues in oral nanoparticle drug carrier uptake and targeting. J Drug Target 2004; 12:65e70.
30. Chen MC, Sonaje K, Chen KJ, Sung HW, A review of the prospects for polymeric nanoparticle platforms in oral insulin delivery. Biomaterials 2011; 32:9826e38.
31. Sonaje K, Lin YH, Juang JH, Wey SP, Chen CT, Sung HW. In vivo evaluation of safety and efficacy of self-assembled nanoparticles for oral insulin delivery. Biomaterials 2009; 30:2329e39.
32. Venkatesan N, Yoshimitsu J, Lto Y, Shibata N. Liquid filled nanoparticles as a drug delivery tool for protein therapeutics. Biomaterials, 2005; 26:7154–63.
33. Fayed B. E., Tawfik A. F., & Yassin A. E. B. Novel erythropoietin-loaded nanoparticles with prolong release and vivo response. Journal of Microencapsulation, 2012; 29(7):650–656.
34. Chen H, Spagnoli F, Burris M, et al. Nanoerythropoietin is 10-times more effective than regular erythropoietin in neuroprotection in a neonatal rat model of hypoxia and ischemia. Stroke. 2012; 43:884–887.
35. Bulmer C., Margaritis A., & Xenocostas A. Production and characterization of novel chitosan nanoparticles for controlled release of rHu-Erythropoietin. Biochemical Engineering Journal, 2012; 68:61–69.
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
Authors who publish with this journal agree to the following terms:
- Authors retain copyright and grant the journal right of first publication with the work simultaneously licensed under a Creative Commons Attribution-NonCommercial 3.0 Unported License. that allows others to share the work with an acknowledgment of the work's authorship and initial publication in this journal.
- Authors are able to enter into separate, additional contractual arrangements for the non-exclusive distribution of the journal's published version of the work (e.g., post it to an institutional repository or publish it in a book), with an acknowledgment of its initial publication in this journal.
- Authors are permitted and encouraged to post their work online (e.g., in institutional repositories or on their website) prior to and during the submission process, as it can lead to productive exchanges, as well as earlier and greater citation of published work (SeeÂ The Effect of Open Access).